BR112014007568A2 - composição farmacêutica, uso e processo para preparar a mesma - Google Patents

composição farmacêutica, uso e processo para preparar a mesma

Info

Publication number
BR112014007568A2
BR112014007568A2 BR112014007568A BR112014007568A BR112014007568A2 BR 112014007568 A2 BR112014007568 A2 BR 112014007568A2 BR 112014007568 A BR112014007568 A BR 112014007568A BR 112014007568 A BR112014007568 A BR 112014007568A BR 112014007568 A2 BR112014007568 A2 BR 112014007568A2
Authority
BR
Brazil
Prior art keywords
preparing
same
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BR112014007568A
Other languages
English (en)
Other versions
BR112014007568B1 (pt
Inventor
Yoshida Hiromitsu
Shimada Kaoru
Kashino Mayumi
Iwata Yasuhiro
Okumura Yoshiyuki
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Publication of BR112014007568A2 publication Critical patent/BR112014007568A2/pt
Publication of BR112014007568B1 publication Critical patent/BR112014007568B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
BR112014007568-9A 2011-10-18 2012-10-18 Composição farmacêutica sólida e seu processo de preparação BR112014007568B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011-228846 2011-10-18
JP2011228846 2011-10-18
PCT/JP2012/076899 WO2013058303A1 (ja) 2011-10-18 2012-10-18 医薬組成物

Publications (2)

Publication Number Publication Date
BR112014007568A2 true BR112014007568A2 (pt) 2017-04-18
BR112014007568B1 BR112014007568B1 (pt) 2022-06-21

Family

ID=48140946

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014007568-9A BR112014007568B1 (pt) 2011-10-18 2012-10-18 Composição farmacêutica sólida e seu processo de preparação

Country Status (12)

Country Link
US (1) US9447065B2 (pt)
EP (1) EP2769718B1 (pt)
JP (1) JP6051466B2 (pt)
KR (1) KR102033970B1 (pt)
CN (2) CN103889414A (pt)
BR (1) BR112014007568B1 (pt)
CA (1) CA2852618C (pt)
ES (1) ES2859676T3 (pt)
MX (1) MX2014004566A (pt)
RU (1) RU2630617C2 (pt)
TW (1) TW201322979A (pt)
WO (1) WO2013058303A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2686675T3 (es) 2013-03-29 2018-10-19 Askat Inc. Agente terapéutico para enfermedad ocular
CN106902358B (zh) * 2015-12-21 2020-07-10 广州市香雪制药股份有限公司 口服制剂及其制备方法
US10213448B2 (en) * 2016-03-25 2019-02-26 Novazoi Theranostics Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof
JP6771594B2 (ja) * 2017-02-15 2020-10-21 大鵬薬品工業株式会社 医薬組成物
CN110404079B (zh) * 2018-04-27 2023-01-24 北京睿创康泰医药研究院有限公司 一种不含碳酸盐、低基因毒性杂质含量的喹啉衍生物或其盐的药物组合物
CA3156590A1 (en) * 2019-11-01 2021-05-06 Piedmont Animal Health Inc. Therapeutic formulations and uses thereof
WO2022138909A1 (ja) * 2020-12-24 2022-06-30 株式会社ダイセル シクロデキストリンにエクオールが包接された包接体、該包接体を含有するエクオール吸収性組成物、及びこれらの製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
AU2002361022A1 (en) * 2001-12-07 2003-06-17 Novartis Ag Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
CA2531116A1 (en) * 2003-07-01 2005-01-20 Michael Hawley Diffusion layer modulated solids
CN1899000A (zh) 2003-11-06 2007-01-17 Ceyx科技公司 用于控制发光设备的视觉强化的方法和装置
BRPI0508254A (pt) * 2004-03-02 2007-07-24 Pharmacia Corp métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
WO2005099691A1 (en) * 2004-03-31 2005-10-27 Pharmacia & Upjohn Company Llc Composition for treating elevated intraocular pressure
WO2006040672A1 (en) 2004-10-12 2006-04-20 Pharmacia & Upjohn Company Llc Substituted cyclopropyl chromene compounds for use in the treatment and prevention of inflammation related conditions
KR20080016689A (ko) 2005-05-27 2008-02-21 파나세아 바이오테크 리미티드 약물주사가 가능한 새로운 형태의 조성물 및 이러한조성물을 위한 조제방법

Also Published As

Publication number Publication date
CN110292575B (zh) 2022-05-13
CN110292575A (zh) 2019-10-01
MX2014004566A (es) 2014-07-09
EP2769718A1 (en) 2014-08-27
WO2013058303A1 (ja) 2013-04-25
US20140256804A1 (en) 2014-09-11
CN103889414A (zh) 2014-06-25
JP6051466B2 (ja) 2016-12-27
BR112014007568B1 (pt) 2022-06-21
TW201322979A (zh) 2013-06-16
KR102033970B1 (ko) 2019-10-18
RU2630617C2 (ru) 2017-09-11
RU2014119946A (ru) 2015-11-27
KR20140092316A (ko) 2014-07-23
EP2769718B1 (en) 2021-03-17
US9447065B2 (en) 2016-09-20
ES2859676T3 (es) 2021-10-04
CA2852618C (en) 2019-06-18
EP2769718A4 (en) 2015-07-01
JPWO2013058303A1 (ja) 2015-04-02
CA2852618A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
BR112014001418A2 (pt) compostos, processo para a preparação dos compostos, e, uso dos compostos
BR112013030163A2 (pt) composto, uso cosmético de pelo menos um composto, composição farmacêutica ou cosmética e processo para preparar um composto.
BR112014004930A2 (pt) processo para a produção de olefinas, e, uso das olefinas
BR112013009486A2 (pt) processo para preparação de formas de dosagem gastrirretentivas multiparticuladas
BR112015008391A2 (pt) processo para o pós-tratamento de um material zeolítico, material zeolítico e uso do mesmo.
BR112014007645A2 (pt) composto heterocíclico, métodos para a preparação de um composto heterocíclico, e, composição farmacêutica
BR112013013127A2 (pt) processo para a preparação de derivados de morfolinil antraciclina
BR112013028959A2 (pt) composto, processo para o preparo de um composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
BR112013006092A2 (pt) laminado, matéria-prima do laminado, método para preparação de um laminado e uso do laminado
BR112013008008A2 (pt) composto, composição farmacêutica e processo para preparar um composto
BR112014015135A2 (pt) polímero baseado em etileno, composição, artigo e processo para preparar o polímero baseado em etileno
BR112014007568A2 (pt) composição farmacêutica, uso e processo para preparar a mesma
BR112015031979A2 (pt) letermovir, formulação farmacêutica oral sólida, uso de uma formulação farmacêutica oral sólida, e processo para preparar letermovir.
BR112013032690A2 (pt) método para produzir um composto, composto, e, uso do mesmo
BR112015002464A2 (pt) processo para a preparação de carbamat-benzoxazinonas, carbamat-benzoxazinonas e utilização das carbamat-benzoxazinonas
BR112014001769A2 (pt) processo para a preparação de 1,4-ciclo-hexanodimetanol
BR112014026564A2 (pt) formulação, uso de uma formulação, e, processo para a preparação de uma formulação
BR112014009684A2 (pt) processo para preparar polímeros, polímero e uso de polímeros
BR112015002609A2 (pt) carbamatos, processo para sua preparação e seu uso
BR112015014630A2 (pt) processo para recuperar um derivado de lignina, derivado de lignina e seu uso, composição
BR112014026543A2 (pt) processo para a preparação de um material zeolítico, material zeolítico sintético, uso de um composto e uso de um material zeolítico
BR112012029225A2 (pt) processo para a preparação de um composto quiral, composto quiral e uso de um composto quiral
BR112013022320A2 (pt) processo para preparar alcanolaminas, e, uso de um catalisador complexo
BR112014031513A2 (pt) composição alimentícia concentrada, processo para preparar uma composição alimentícia concentrada e uso da composição
BR112013031575A2 (pt) composto peptídico ciclado de estrutura principal, composição farmacêutica, uso de composto, e, processo para a manufatura de um composto.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ASKAT INC. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/10/2012, OBSERVADAS AS CONDICOES LEGAIS